The third batch of collection began with 86 rules, including metformin, which had "escaped from the list".

On July 21, Shanghai Sunshine Pharmaceutical Procurement Network issued a notice from the Joint Procurement Office, which covers the collection of some basic drug-related information, involving 86 product regulationsin addition to amoxicillin granules (0.125g), adsacydin injections (100mg), amino glucose oral resustonic serotones (0.25g, 0.75g), apixaban oral respute (2.5mg), anacura oral permanent release agent (1mg), etc., including the second set of "escape list" of metforminfrom the list, this entry into the third batch of metformin involved a total of 3 product regulations, including metformin slow release control release agent form (0.5g), metformin oral frequentrelease agent form (0.25g, 0.5g)data show that metformin is a commonly used anti-sugar drug in clinical practice, of which metformin slow-release control agent form belongs to the national medical insurance Class BAccording to PDB statistics, domestic sales of metformin in 2016 amounted to nearly 445 million yuan, an increase of 15% YoYdomestic sales of metformin in 2017 amounted to nearly 510 million yuan, an increase of 14.3% YoYalso according to public data found that the domestic oral blood glucose regulating drug market is growing steadily, of which metformin ranked second, accounting for 19%, the top ranking is acapoccosis (accounting for 37%)according to industry statistics, metformin slow release agent form (0.5g) through / like through the consistency evaluation of about 17 enterprises, including Zhengda Qing, stone drug Ouyi, Baiyang Pharmaceuticals, etc.;because of its more enterprises through consistency evaluation, the competition is very fierceNovember 2019, Hebei Province has issued a document for 15 kinds of urban and rural residents of hypertension, diabetes outpatient drugs for collection, metformin oral frequently released agents of metformin is expected to purchase 500 million tabletsthe winning documents show that the winning stone drug Europa hydrochloride (0.5g) price fell to 0.043 yuan / tabletthe price is 57.9% lower than its high price limit of 0.102 yuan/chipit is understood that the raw materials of hydrochloric acid metformin for the group's own production, the company is confident that such pricethe advantages of self-producing also made the company's hydrochloric acid metformin as early as August 9, 2018in the second batch of collection, some experts have analyzed that, as a diabetes drug, the community generally believed that metformin should be in the catalog, because the variety is highly competitive, and the use of large, but it involves hundreds of enterprises, the impact on enterprises is too big, it is difficult to set the rulesbut industry veterans have also predicted that the number of domestic use of metformin is huge, in the short term can not find alternative products, into the collection is a thing of hiding" the future depends on who has the APIthe price of metformin is already very lowsome enterprises almost in the cost price a little higher, which means that after the collection of a lot of enterprises will directly give up competition" it is understood that the third batch of national drug catalogue statistics, reporting work was completed in the middle of this month, the official catalogue and tenders will be announced at the end of the monthit is worth noting that the notice is also clear, this information collection work is only used for related work of the row and research, not as a centralized procurement of drugs enterprise declaration basis, specific declaration of enterprise qualification and declaration of varieties of eligibility to the procurement documentsthis also means that these 86 rules can not be fully identified as the collection of the standard, there is room for adjustment.